{"schema_version":"secwatch.filing_event.v1","accession":"0001636422-24-000072","form_type":"8-K","ticker":"HCAT","cik":"0001636422","company_name":"Health Catalyst, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.360258+00:00","generated_at":"2026-06-02T06:08:39.595520+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Health Catalyst Q1 revenue $74.7M, Adj EBITDA $3.4M; beats guidance mid-point","bullets":["Q1 total revenue $74.7M (up 1% YoY), net loss $20.6M (improved 38% from $33.2M loss).","Adjusted EBITDA $3.4M above Q1 guidance range of $2M-$4M.","Reiterates FY2024 revenue guidance $304M-$312M and Adj EBITDA $24M-$26M.","Q2 2024 guidance: revenue $73.5M-$76.5M, Adj EBITDA $5M-$7M.","New platform branded Health Catalyst Ignite; expansion with Saudi German Health announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001636422-24-000072","json":"https://secwatch.observer/filing/0001636422-24-000072.json","markdown":"https://secwatch.observer/filing/0001636422-24-000072.md","text":"https://secwatch.observer/filing/0001636422-24-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636422/000163642224000072/0001636422-24-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636422/000163642224000072/hcat-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:08:39.595520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b172828b006d9c24aca2e1a823a369d51d28302","claim":"Health Catalyst, Inc. reported the quarter ended March 31, 2024 results: revenue $74.7 million.","evidence_excerpt":"today reported financial results for the quarter ended March 31, 2024. “For the first quarter of 2024, I am pleased by our strong financial results, including total revenue of $74.7 million and Adjusted EBITDA of $3.4 million, with these results beating the mid-point of our quarterly guidance on each metric. This financial performance demonstrates our ability to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636422/000163642224000072/0001636422-24-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$74.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}